About the Journal
International Journal of Bioinformatics and Computational Biology is a peer-reviewed hybrid open-access journal launched in 2023 concerning recent advancements and emerging technology in computational biology and bioinformatics. Journal also covers a wide range of topics including synthetic biology and structural genomics. Journal publishes both experimental and theoretical papers.
Journal Particulars
📧 lifesciences.editor@stmjournals.com
📞 0120-4781254/9218093693
Latest Articles
Volume: 03, Issue: 02, Year: 2025
Nupur Singh, Amit Singhal
Keywords: DNA structure, DNA cryptography, DNA techniques, comparison, utilization.
Neerja Shukla, Anita Singh, Rahila Khan, Shashikant Verma, Anushka Shukla, Kumari Suman, Bechan Sharma
Keywords: Indomethacin Derivatives, Poglani Factor (Q), LOO (Leave-One-Out), Anti-inflammatory Activity, and Potency.
E.Dhiravidachelvi, S.Vengatesh Kumar, K.Sabitha Banu, H.Peer oli
Keywords: Eye disease classification, k-means clustering, image segmentation, machine learning, ensemble voting, Decision Tree
Nandana V A
Keywords: Chandanasava, renal tubular acidosis, Pendrin, Carbonic Anhydrase II, molecular docking, phytochemicals, acid-base homeostasis
Abhimanyu Chauhan, Chakresh Kumar Jain
Keywords: Major Depressive Disorder (MDD) is a prevalent neuropsychiatric disorder with limited treatment efficacy and significant side effects associated with conventional antidepressants.
| Metric | Value |
|---|---|
| Data From | January 2024 |
| Published Articles | 26 |
| Ahead of Print Articles | 1 |
| Acceptance Time | 57.73 Days |
| Publication Time | 89.55 Days |
Special Issue Topic
Journal Menu
Biomarker’s role in Cancer Detection
Abstract Submission Deadline : 30/11/2023
Manuscript Submission Deadline : 25/12/2023
Special Issue Description
Biomarkers give a strong and dynamic way to deal with understanding the range of malignancies with applications in observational and scientific studies of disease transmission, randomized, clinical trials, screening, diagnosis, and forecast. In cancer examination and location, a biomarker alludes to a substance or cycle that is indicative of the presence of disease in the body. It may very well be either a particle secreted by malignancy itself or a particular reaction of the body to the presence of cancer. Biomarkers can be estimated in natural media like tissues, cells, or liquids. Cancer biomarkers have changed our way to deal with patient considerations in numerous malignant growth types. The dogma concerning malignant growth markers has been that without a trace of powerful therapies, the best way to deal with the disease was the early diagnosis, trailed by surgical intervention before the cancer had spread. Although a couple of viable methods, for example, DRE for prostate disease, needle biopsy, and mammography for bosom malignant growth have been effectively utilized in the early determination of disease, scarcely any new symptomatic markers have arisen. They have significant expected benefits for patients, especially in adding to “customized” medication, and further developed biomarkers ought to at last prompt enhancements in results and more productive, safe, financially savvy, and proof-based utilization of well-being assets. More explicitly as far as clinical utility, a malignant growth biomarker may gauge the risk of developing the disease in a particular tissue or, on the other hand, may quantify the hazard of malignant growth movement or expected reaction to treatment. Other than giving helpful data in directing clinical navigation, malignant growth biomarkers are progressively connected to explicit subatomic pathway liberations as well as disease pathogenesis to legitimize the use of specific remedial/interventional systems. The reasonable system of disease biomarker advancement has additionally been developing with the quick extension of our omics investigation capacity of clinical biospecimens because of the conventional way of biomarker deployment. In any case, the improvement of many – omic advancements, like genomics and proteomics, has permitted us to monitor enormous numbers of key cellular pathways. This has empowered the distinguishing proof of biomarkers and signaling molecules related to cell development, cell death, and cell metabolism. These regions additionally work in checking the functional disturbance, molecular and cellular damage, and damage response.
Keywords
Biomarkers , Malignancies , Cancer , Dogma , Clinical
Manuscript Submission information
Manuscripts should be submitted online via the manuscript Engine. Once you register on APID, click here to go to the submission form. Manuscripts can be submitted until the deadline.
All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the email address:info@stmjournals.com for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a Double-blind peer-review process. A guide for authors and other relevant information for the submission of manuscripts is available on the Instructions for Authors page.
Participating journals:
Abbrivation
Since
2023
APC
950 $